Research groups
Websites
-
MRC Weatherall Institute of Molecular Medicine
Research Institute
-
MRC Molecular Haematology Unit
Research Unit
-
Oxford Single Cell Biology Consortium
.
-
Medical Research Council
I am an MRC Senior Clinical Fellow
-
NIHR Oxford BRC
Principal Fellow
DPHIL OPPORTUNITIES AVAILABLE
Adam Mead
PhD MRCP FRCPath
Professor of Haematology
- Consultant Physician
- CRUK Senior Cancer Research Fellow
Normal and malignant haematopoietic stem cell biology
Normal and malignant haematopoietic stem cell biology
I trained in medicine and haematology at the University of Oxford and UCL and completed my PhD at UCL in 2007. I am currently funded by a CRUK Senior Cancer Research Fellowship.
The overarching focus of my research group is to characterise genetic and cellular heterogeneity in myeloproliferative neoplasms (MPN) and related myeloid neoplasms with the ultimate goal to improve the diagnosis, risk-stratification and treatment of these largely incurable forms of blood cancer. Our work using cutting edge techniques in single cell genomics and in vivo models has revealed hitherto unrecognised heterogeneity of cancer stem cells, including a key role for inflammation in promoting therapy resistance and genetic evolution. Understanding the interplay between genetic, metabolic and inflammatory factors in the clonal evolution of myeloid malignancies is now the key focus of my research group.
My research is closely linked with my clinical practice based at Oxford University Hospitals NHS Trust where I am myeloid clinical lead. I am or have been the principal/chief investigator for over 50 trials. I led the development of JAK2 inhibitor therapies in the UK for patients with MPN as chief investigator, scientific lead or co-investigator on multiple key clinical trials (ROBUST, MAJIC, MITHRIDATE, PERSIST-1 and -2, MPDRC114, PHAZAR, PAC203, FEDORA, PROMise).
Key publications
-
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Journal article
Harrison CN. et al, (2023), J Clin Oncol
-
In utero origin of myelofibrosis presenting in adult monozygotic twins.
Journal article
Sousos N. et al, (2022), Nat Med, 28, 1207 - 1211
-
Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.
Journal article
Louka E. et al, (2021), J Exp Med, 218
-
Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets.
Journal article
Psaila B. et al, (2020), Mol Cell, 78, 477 - 492.e8
-
Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.
Journal article
Rodriguez-Meira A. et al, (2019), Mol Cell, 73, 1292 - 1305.e8
-
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.
Journal article
Giustacchini A. et al, (2017), Nat Med, 23, 692 - 702
-
Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.
Journal article
Booth CAG. et al, (2018), Cancer Cell, 33, 274 - 291.e8
-
Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.
Journal article
Mead AJ. et al, (2017), J Exp Med, 214, 2005 - 2021
-
Germline JAK2 mutation in a family with hereditary thrombocytosis.
Journal article
Mead AJ. et al, (2012), N Engl J Med, 366, 967 - 969
-
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.
Journal article
Mead AJ. et al, (2007), Blood, 110, 1262 - 1270
Recent publications
-
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Journal article
Harrison CN. et al, (2023), J Clin Oncol
-
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
Journal article
Mascarenhas J. et al, (2023), J Clin Oncol
-
Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.
Journal article
Ryou H. et al, (2023), Leukemia
-
Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia.
Journal article
Rastogi N. et al, (2022), Leukemia
-
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.
Journal article
Schnegg-Kaufmann AS. et al, (2022), Blood
ORC-ID
0000-0001-8522-1002